Retatrutide

Simultaneous agonism at GIP, GLP-1, and glucagon receptors. Phase-2 trial data (Eli Lilly, 2023). 39 amino acids, MW 4,731 Da. ≥99% HPLC purity. Janoshik COA available on request. For research use only.